Systematic Review

Sissel Breivold Roland, Are Hugo Pripp, Mbachi Ruth Msomphora and Gunnvald Kvarstein*

The efficacy of botulinum toxin A treatment for tension-type or cervicogenic headache: a systematic review and meta-analysis of randomized, placebo-controlled trials

https://doi.org/10.1515/sjpain-2021-0038
Received February 19, 2021; accepted May 4, 2021; published online June 4, 2021

Abstract

Objectives: The pathogeneses of chronic tension-type headache (CTTH) and cervicogenic headache (CEH) are not well established. Peripheral activation or sensitization of myofascial nociceptors is suggested as a potential mechanism and injections of botulinum toxin (BONTA) have thus been used in the treatment for both headache conditions. BONTA inhibits the release of acetylcholine at the neuromuscular junction and inhibits contraction of skeletal muscles. If the pain is precipitated by increased tone in cervical muscles, local injections of BONTA could represent a prophylactic measure. However, the treatment is still controversial, and a thorough assessment of the current evidence is required. This review aims to assess the evidence of BONTA injection as a prophylactic treatment for CTTH and CEH by reviewing and examining the quality of placebo-controlled, randomized trials.

Methods: Data sources: we searched in the following databases: PubMed (including Medline), Embase, Cochrane Central register of Controlled Trials, Cinahl, Amed, SCOPUS and Google Scholar including other repository sources. Both MeSH and free keywords were used in conducting the systematic search in the databases. The search covered publications from the root of the databases to November 2020.

Study eligibility criteria: The review included RCTs, comparing single treatment of BONTA with placebo on patients with CTTH or CEH above 18 years of age, by measuring pain severity/relief or headache frequency.

Data extraction: The following data were extracted: year of publication, country, setting, trial design, number of participants, injection procedure, BONTA dosages, and clinical outcome measures.

Study appraisal: To assess validity and quality, and risk of bias, the Oxford Pain Validity Scale, Modified Jadad Scale, last version of Cochrane Collaboration’s tool for assessing risk of bias (RoB 2), and the CONSORT 2010 Checklist were used. The trials were assessed, and quality scored independently by two of the reviewers. A quantitative synthesis and meta-analyses of headache frequency and intensity were performed.

Results: We extracted 16 trials, 12 on prophylactic BONTA treatment for CTTH and four on CEH. Of these 12 trials (8 on CTTH and 4 on CEH) were included in the quantitative synthesis. A majority of the trials found no significant difference on the primary outcome measure when BONTA treatment was compared with placebo. Three “positive” trials, reporting significant difference in favor of BONTA treatment, but two of these were hampered by low validity and quality scores and high risk of bias.

Conclusions: There is no clear clinical evidence supporting prophylactic treatment with BONTA for CTTH or CEH.

Keywords: botulinum toxin A; chronic tension-type headache; cervicogenic headache; injection; systematic review.

*Corresponding author: Gunnvald Kvarstein, Pain Clinic, Division of Surgical Medicine and Intensive Care, University Hospital of North Norway, Tromsø, Norway; and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway, E-mail: gunnvald.kvarstein@uit.no

Sissel Breivold Roland, Department of Orthopedics, Finnmark Hospital Trust, Hammerfest, Norway; Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway,

Are Hugo Pripp, Oslo Centre of Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway

Mbachi Ruth Msomphora, Research and Publishing Support, Department of Library services, UiT The Arctic University of Norway, Tromsø, Norway

Open Access. © 2021 Sissel Breivold Roland et al., published by De Gruyter. This work is licensed under the Creative Commons Attribution 4.0 International License.
Introduction

Headache is one of the most costly health problems [1]. Chronic tension-type headache (CTTH) is characterized by bilateral headache ≥15 days a month and has a 1-year period prevalence of 2.2% [2]. CEH is characterized by a unilateral headache and the prevalence of cervicogenic headache (CEH), is less frequent, but affects about 15% of patients with a chronic headache [3–5]. Both types of headache account for high rates of disability [4, 6].

The underlying pathophysiology of these two types of headache is not well established [7, 8]. Tension-type headache has for years been explained by nociceptive input from muscular tender or trigger points (MTrP’s) [9], due to a disturbed function of the neuromuscular endplate and exaggerated muscular depolarization with contractions, compressing the small vessels and thereby leading to muscular ischemia [10]. This explanation has later been challenged [11, 12]. Psychological conditions like anxiety, depression [13, 14] and stress [15] seem to play an important role, and experimental research indicates a sensitization of sensory pathways and disturbed pain regulation [16], possibly mediated by serotonergic [17], cholinergic [18], and inflammatory mechanisms [19, 20]. CEH is by the International Headache Society (IHS) defined as a secondary disorder where cervical spine components like spinal vertebrae, intervertebral discs and soft tissue elements [21, 22], and musculoskeletal dysfunction are believed to play an important role [23–25].

Both CTTH and CEH are conditions difficult to treat. Botulinum toxin A (BONTA) is used clinically for several conditions, including migraine [26], but for CTTH and CEH the treatment has been based on the notion of a disturbed neuromuscular function [27]. The compound blocks the release of acetylcholine at the neuromuscular junction and may partially paralyze muscles for a few months [28–31]. A systematic review and meta-analysis published in 2012, focused on BONTA treatment for episodic and chronic migraine, chronic daily headache and CTTH [32]. In this review CTTH BONTA was not associated with fewer attacks per month. Two more recent reviews, including low quality studies like non-controlled trials and prospective as well as retrospective cohort studies, however, concluded that botulinum toxin seems to be effective in the management of CTTH [33, 34]. The evidence for BONTA treatment for CEH is limited and in a review, published in 2002 [35], only one randomized controlled trial [36] and a case study [37] were identified, and the results were contradictory. Thus, there is a need for an update on the clinical evidence of BONTA treatment for CTTH and CEH, which is based on high-quality studies.

Aims

This systematic review and meta-analysis are limited to placebo-controlled, randomized trials studying the efficacy and safety of BONTA as prophylactic treatment of CTTH and CEH. Our aim was to examine and rank the quality, validity, and risk of bias of the trials in order to critically assess the clinical evidence of one session with BONTA injections as a prophylactic treatment for CTTH and CEH. Ethical approval was not required for a review of selected publications.

Methods

Criteria for considering trials relevant for this review

A well-focused question based on the PICO1 framework was formulated in order to ensure the identification of appropriate search terms for finding relevant literature-evidence in writing this systematic review [38, 39]. The standard PICO terms, herein, were translated as follows:

- Type of participants (Population): adult humans with tension-type headache or cervicogenic headache. Type of interventions (Intervention): local intramuscular injections including muscular trigger points (MTrP) with botulin toxin A. Control/Comparison: placebo. Type of outcome measures (Outcome): reduced frequency (days with headache) or reduced headache severity (pain intensity or pain relief). Based on the PICO terms as indicated above, the search questions formulated was as follows: in adult humans with tension-type headache or cervicogenic headache, are local intramuscular injections (including MTrP) with botulin toxin A superior in reducing days with headache or headache severity (pain relief) compared to placebo?

Search methods for identification of studies

A systematic search strategy, developed by the physicians at the University Hospital of Northern Norway (UNN), Tromsø and at the Finnmork Hospital Trust, Alta, in cooperation with the Senior Information Specialist at the Medical Library of UIT The Arctic University of Norway and another librarian from the Unit for Applied Clinical Research - Norwegian University of Science and Technology, was conducted to identify relevant studies for this systematic review. The systematic searches were repeatedly conducted until November 2020 using electronic databases PubMed, Embase, Cinahl, Amed, Cochrane Central Register of Controlled Trials, and SCOPUS. Besides, reference lists of systematic reviews and included articles were manually scanned to expand the data set. The final searches were not restricted on language or publication date, but conducted to up-to-date 03 November 2020. The search strategy was based on the following key

---

1 The acronym “PICO” stands for P, Population (who/what); I, Intervention (How); C, Control/Comparison (What is the main alternative); O, Outcome (What are we trying to measure).
concepts: tension-type headache or cervicogenic headache, Botulinum
toxin, reducing headache frequency i.e. days with headache or
reducing headache severity. An example of the search strategy, where
both MeSH and free keywords were used, as applied in PubMed, can be
viewed as follows:

((((tension headache) OR (Tension-Type Headache)) OR
(headache disorders, secondary)) OR (cervicogenic headache)) OR
(cervical)) AND (((Botulinum Toxins) OR (Botulinum)) OR (botulinum
toxin)) OR (toxin)) OR (toxins)) AND (((duced headache) OR
(headache)) OR (reduced headache severity)) OR (severity)) OR (pain
relief) OR (reduced headache days)) OR (headache free days)) Filters: Clinical
Trial, Randomized Controlled Trial, Humans.

Besides, a step by step search strategy table can be viewed in
Supplementary Appendix 1 among the e components.

Google Scholar was also searched for triangulation purposes, i.e.
to ensure the identification of all relevant evidence available on the
herein topic and the websites searched, using the reference list
of identified studies. The primary author of one publication was
contacted for further information.

We additionally searched for ongoing or recently completed and
unpublished studies through other repository sources such as, www.
clinicaltrials.gov, https://papas.cochrane.org/, http://www.isrctn.
com/ and https://www.crd.york.ac.uk/prospero/. However, none of
the identified articles/trials in the latter registers were found eligible
either due to double registration or because they were not completed
such that results were not available.

Selection criteria for identification of eligible studies

The selection of eligible trials, included in this systematic review, was
conducted in accordance with the PRISMA statement guidelines [40,
41], and developed in close collaboration with the two librarians.
The potentially eligible trials selected were assessed on the efficacy of
BONTA. To assess this, only prospective, placebo-controlled trial,
involved patients of ≥18 years old and with CTTH or CEH, receiving
BONTA injections in selected skeletal muscles in the upper quarter of
the body; and assessed by outcomes on pain severity/pain relief and
number of headache (or headache-free) days per week(s) or month,
were included. The BONTA treatment could be combined with phys-
otherapies as well as prophylactic and analgesic medications. How-
ever, trials, including patients with neurological diseases (dystonia,
torticollis) or other pain conditions (such as temporomandibular
order or phantom limb pain), were excluded. Only full text available
trial reports were selected for inclusion. The publications subjected to
multiple registration across or within databases, were excluded.

Screening and data extraction for analysis

Screening by trial headings and abstracts of potentially relevant trials
was conducted independently by two of the four authors (SBR and
GK). Full text copies of potentially relevant trials were retrieved and
independently read and reassessed manually by the same authors.
Discrepancy on eligibility was discussed until agreement was
achieved. The bibliographies of the retrieved eligible articles and
systematic reviews were further checked for additional references.

Data extraction from the relevant included trials was performed and
was comprised of the following: year of publication, country of origin,
setting, trial design, number of participants, subject characteristics,
information about the intervention procedure, BONTA dosages, and
clinical outcome measures.

Assessment of validity, quality and risk of bias

Each trial underwent a critical assessment by validated assessment
tools such as validity, quality and risk of bias. The scores were
compared, and discrepancies resolved by discussion between the two
authors herein (SBR and GK).

The Oxford Pain Validity Scale for randomized trials (OPVS)
covers five items: blinding, sample size of each trial group, outcomes,
and demonstration of internal sensitivity [42, 43]. The last, main item
includes four sub-items: definition of outcomes, data presentation,
statistical testing, and handling of dropouts. With a total of eight
criteria the score ranges from 0 to 16 points [44].

The Modified Jadad Scale consists of five items derived from the
Oxford quality scale [40] focusing on randomization, blinding, with-
drawals and dropouts and three extra items on criteria for eligibility, and
methods to assess adverse events and statistical analysis. The sum score
ranges from 0 to 8 points. The quality scale has shown a good interrater
agreement with an intraclass correlation coefficient at 0.9 [41].

Study quality was also assessed by the number of confirmative
responses to the CONSORT 2010 Checklist (CONsolidated Standards
of reporting trials = CCL-25). The list focuses on how the trial is designed,
analyzed, and results are interpreted and includes 25 items. As some
items include sub-items, it provides a set of 37 yes or no responses
depending on whether the item is reported or not. The checklist is
designed for planning trials [45], and not a quality assessment tool per
se. However, the number of responses provides a thorough consider-
ation of several quality related study characteristics, and several
journals have adopted the checklist in their evaluation of papers in
order to increase the number of high-quality reports, improve RCT
interpretation, and to minimize biased conclusions [46].

With an overlap of items between the different scoring systems,
we found a close correlation between the scores of OPVS and Modified
Jadad (Spearman correlation, N: 15, rho: 0.79, p<0.001) and CCL-25
(Spearman correlation, N:15, rho: 0.67, p<0.006).

Risk of bias was assessed for the individual trial by the revised
Cochrane Collaboration’s tools for assessing risk of bias (RoB 2) [47,
48]. The RoB 2 tools are derived from the original Cochrane risk-of-bias
tool for randomized trials (ROB 1) either with a parallel or cross-over
design [48, 49] and is structured into a fixed set of domains, focusing
on different aspects of trial design, conduct, and reporting such as
randomization, blinding, differences in baseline levels, measurement,
missing and selection of outcome data (see Supplementary Table 8).
The risk of bias is generated by an algorithm, based on answers to the
signalling questions and is expressed either by ‘low’ or ‘high’ or by the
intermediate option ‘some concern of’ risk of bias.

Sensitivity analyses

Heterogeneity was assessed by I² statistics, p-values, Q statistics,
degree of freedom and by calculating the influence of each trial on
standardized mean difference (SMD) by excluding one by one in
separate analysis to investigate the influence on the overall results
[50]. To explore potential publication bias we generated Funnel plots
while bias due to small trials was assessed by the Egger regression test
[51]. As the trials were few and test results rely on assumptions, fixed
effect and Mandel–Paule aka empirical Bayes estimator meta-analysis were added [52]. Finally, we assessed the impact of potential covariates on the effect size using a meta-regression-based technique and with robust variance estimation in meta-regression if dependent effect sizes from the same study were included [53–56].

Meta-analysis and other statistical analyses

The quantitative synthesis of effect sizes was carried by a statistician within the team and based on SMD as effect size for the two common primary outcomes, pain intensity and pain frequency. Both are recommended and used in most clinical trials on headache. The effect sizes were calculated from final frequency [57], mean values or change from baseline and standard deviations, standard error of the means, confidence intervals or p-values described in the manuscripts, tables, or depicted in figures. Median and range were converted to mean and standard deviation using the method by Wan et al. [58]. The meta-analysis with tests and plots were generated by the statistical package Stata version 16 (Stata Corp, College Station, TX, USA) with the user-developed packages metan, metafunnel, metabias, metareg and robumeta. To achieve comparable dosages of abobotulinumtoxin A (Dysport) and onabotulinumtoxin A (Botox) for pooled analyses across the trials, we converted dosages of abobotulinumtoxin A by a divisor of 2.5 [59].

Due to skewed data non-parametric tests were applied for other statistical analyses. For continuous data bivariate correlations were carried out by the Spearman’s test and group comparisons by Independent-Samples Kruskal–Wallis Test. For categorical data comparisons, the Fisher exact test was used. Significance values were adjusted by the Bonferroni correction for multiple tests. These correlations and group comparisons were performed by the statistical package IBM SPSS Statistics 26.

Results

Trials included

The database searches identified 360 publications on the topic botulinum toxin type A treatment of tension-type headache and cervicogenic headache. By reading titles and abstracts, 455 publications were excluded due to inappropriate diagnosis, intervention, design and/or type of paper, or due to multiple registration within or across databases, full text not available or because the trial was not completed (see Figure 1; flow chart). Thus, 16 trials were finally extracted for the review [36, 59–73]. The trials were published between 1999 and 2012 with an aim to study the clinical efficacy/effectiveness (or “beneficial effect”). Five trials [36, 59, 68, 70, 72] also aimed to assess safety of BONTA injections. 12 trials included patients with CTTH [59–70] while four trials included patients with CEH [36, 71–73] (Figure 2).

Sample size

The 16 trials represent a total sample of 954 participants, 823 with CTTH and 131 with CEH, and a total of 571 were assigned to receive BONTA injections. The sample sizes varied across the trials from 8 to 300 patients with a median of 36.5. Only five trials included a total sample of >40 participants [59, 60, 62, 67, 68]. In three CTTH trials more than 50 participants received BONTA [59, 67, 68], while in nine trials the number of participants was less than 20 [36, 61, 63, 65, 66, 69–72] (see Table 1). Four trials [59, 65, 67, 72] performed sample size calculation, but in one trial as a post hoc analysis [72]. In two trials they did either not achieve [67] or present [59] the calculated sample size.

Dropouts

Eleven trials reported rates of dropouts, with a range from 0–28% and a median of 6% (see Table 1). Eleven of the 16
Table 1. Description of 16 randomized placebo-controlled trials on botulinum toxin A treatment for chronic tension type or cervicogenic headache.

| First Author Year, Country Setting | Design | Sample/Experimental/Control | Diagnostic criteria Injection technique, Brand BONTX name Total and site dosages | Group comparisons during follow up based on response rates or changes in endpoints from baseline | P values/Statistical significance |
|-----------------------------------|--------|-----------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|-------------------------------|
| Smuts JA 1999 South Africa Hospital and private neurology practices | Design: DB RCT parallel 2 arms Follow up: 12 w Diary 4 w intervals | N: 41 E/C: 22/15 Dropout: 10% ITT: NA Age: 28 pts < 40, 23 pts 40-55 F: 73% | CTHH associated with pericranial muscles IHS 1997. Injections: 12 fixed sites EMG guided Botox<sup>®</sup> dosage: 100 U, per site: 8.3 U | After 4, 8 and 12 w Primary: NA Response rate (≥ 25% improvement: BONTX 13/22, Placebo 2/15 Headache intensity (0-5), Headache frequency (headache-free days/month). Acute medication EMG, Chronic pain index, Adverse events | NA NA NA |
| Rollnik JD 2000 Germany Neurology Dept. | DB RCT parallel 2 arms Follow up: 12 w Diary 4 w intervals | N: 21 E/C: 11/10 Dropout: NA ITT: NA Age: 37 (19-63) F: 62% | Episodic and CTHH IHS 1988 Injections: 10 fixed sites Dysport<sup>®</sup> dosage: 200 U, per site: 20 U | After 4, 8 and 12 w Primary: NA Pain intensity (VAS 0-10) Headache frequency and headache attack duration Total tenderness Score, Pressure pain thresholds Clinical global impression, NHP, Acute medication ELQ (in favor of placebo) | NS NS NS NS p<0.047 |
| Schmitt WJ 2001 Switzerland Neurology Dept. | DB RCT parallel 2 arms Follow up: 8 w Diary 4 w intervals | N: 60 E/C: 30/29 Dropout: 3% ITT: NA Age: 46 (18-78) F: 60% | CTHH IHS Injections: 8 fixed sites Botox<sup>®</sup> dosage: 20 U, per site: 2.5 U | Primary (1-4 w and 5-8 w): Pain severity (VAS) and WHIMPI (0-7) Secondary (1-4 w and 5-8 w): Responder rates (≥ 25% pain red.) Headache frequency (headache-free days), Duration of headache, Daily activity, Acute medication Affective distress and angry mood 4 w Side effects: Primary (6 and 12 w): AUC = Pain intensity (0-4) x pain duration (hrs/day) Secondary (6 and 12 w): EMG of m. temporals (12 w) Primary: Headache intensity (0-10) Headache frequency (days/month) Secondary: Acute medication Treatment: days/month Acute medication Global impression of improvement (5-point scale). Side effects | NS NS NS NS NS p<0.05 NS |
| Rollnik JD 2001 Germany Neurology Dept. | DB RCT parallel 2 arms Follow up: 12 w Diary 6 w intervals | N: 8 E/C: 4/4 Dropout: NA ITT: NA Age: 54 (43-65) F: 38% | CTHH IHS 1988 Injections: 22 fixed sites Dysport<sup>®</sup> dosage: 500 U, per site: 15-30 U | Primary (6 and 12 w): AUC = Pain intensity (0-4) x pain duration (hrs/day) Secondary (6 and 12 w): EMG of m. temporals (12 w) Primary: Headache intensity (0-10) Headache frequency (days/month) Secondary: Acute medication Treatment: days/month Acute medication Global impression of improvement (5-point scale). Side effects | NS p = 0.043 |
| Kokoska MS 2004 USA Head and Neck Surgery Dept | DB RCT parallel 2 arms Follow up: 6 months (max.) Diary 4 w intervals | N: 40 E/C: 20/20 Dropout: 0% ITT: No Age: 47 (-) F: 78% | CTHH IHS Injections: 10 fixed. Botox<sup>®</sup> dosage: 50 U, Per site: 5 U | Primary: Headache intensity (0-10) Headache frequency (days/month) Secondary: Acute medication Treatment: days/month Acute medication Global impression of improvement (5-point scale). Side effects | p<0.05 NS NA |
| Padberg M 2004 Netherlands Neurology dept. | DB RCT parallel 2 arms Follow up: 12 w Diary 4 w intervals | N: 40 E/C: 19/21 Dropout: 0% ITT: No Age 45 (19-79) F: 70% | CTHH IHS 1988 Injections: 14 symptom evaluated Botox<sup>®</sup> dosage: 1 U/kg or max. 100 U, per site: 10-20 U | Primary: (0-12 w) Headache intensity (VAS 0-100) Secondary: (0-12 weeks): Responder rate (≥ 55% reduction in pain intensity) Headache frequency (days/month) Headache duration (hrs/day), Treatment: days/month Acute medication Global impression of improvement (5-point scale). Side effects | NS NS NS NS NS NS NS |
| First Author Year, Country Setting | Design | Sample/Experimental/Control Dropout rate Age: mean years (SD or range) Female ratio (F %) | Diagnostic criteria Injection technique, Brand BONTX name Total and site dosages | Group comparisons during follow up based on response rates or changes in endpoints from baseline | P values/Statistical significance |
|-----------------------------------|--------|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|----------------------------------|
| Relja M 2004 Croatia One Neurology Dept. | DB RCT cross-over 2 arms Follow up: 8 w Diary 4 w intervals | N: 16 Dropout: NA ITT: NA Age: NA F: 56% | CTTH IHS 1988 Injections: symptom evaluated Botox® dosage: 45-90 U. | After 4 w: Primary: NA Headache severity (0 (none) - 3 (severe)) Headache-free days per month Total tenderness Primary (6-12 w): Headache intensity (VRS 0-4) x headache duration (hrs/day) (AUC) Secondary (6-12 w): Headache frequency (days/week) Symptomatic treatment days/week Muscular tenderness Beck depression inventory, Sleep duration (diary). Acute medication Side effects | p<0.05 p<0.05 |
| Schulte-Mattler WJ 2004 Germany 2 neurology dept. | DB RCT parallel 2 arms Follow up: 18 w Diary 6 w intervals | N: 112 E/C: 53/54 Dropout: 4% ITT: NA Age: 46 (14) F: 46% | CTTH IHS 1988 and IASP 1994 Injections: 22 fixed sites Dysport dosage: 500 U, per site: 15-30 U | | NS NS NS NS NA |
| Silberstein SD 2006 USA 22 North American and 7 European study centres | DB RCT parallel 6 arms Follow up: 16 w Diary 4 w intervals | N: 300 E/C: 250/50 E/C: 49 /51/ 52/51/47/50 Dropout: 7% ITT: 300 Age: 43 (18-65) F: 62% | CTTH IHS 1988 Injections: 10 fixed sites Botox® dosages: 150 U, 100 U, 86, and 50U, per site: 3.3-60 U | | NS NS NS NS |
| Straube A 2008 Germany 19 study centers | DB RCT parallel 3 arms Follow up: 12 w Diary 4 w intervals | N:125 E/C: 93/32 Dropout: 6% ITT: 118, PP: 115 Age: 42 (19-69) F: 53% | CTTH IHS 1988 Injections: 18 fixed sites Dysport® dosages: 420/210 U, per site: 11.7 U-23.2 U | Primary (4-8 w): Headache frequency (headache–free days) Secondary (8-12 w): Headache frequency (headache–free days) U Secondary (8-12 w): Headache duration (days) Headache intensity (VRS, 0-3) and Total Tenderness Score Acute medication Intercurrence with daily life and Beck Depression Inventory Global assessment rated by physician and by patient Side effects: mild and transient at 12 w 420 U:27% and 210 U:25% vs placebo:7% | NS NS p<0.05 NS NS NS |

**Table 1.** (continued)
Table 1. (continued)

| First Author Year, Country Setting | Design | Sample/Experimental/Control Dropout rate Age: mean years (SD or range) Female ratio (F %) | Diagnostic criteria Injection technique, Brand BONTX name Total and site dosages | Group comparisons during follow up based on response rates or changes in endpoints from baseline | P values/Statistical significance |
|------------------------------------|--------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------|----------------------------------|
| Hamdy SM, 2009 Egypt Neurology Dept. | SB RCT parallel 2 arms Follow up: 12 w Diary: 4 w intervals | N: 28 E/C: 14/14 Dropouts: NA ITT: NA Age:37 (25-50) F: 68% | CTHH IHS 2004 Injections: Combined fixed sites and symptom evaluated, Number: NA Total Botox® dosage: 30-80 U, pr. site:2-12 U | Primary: Headache frequency (6 and 12 w) Headache severity (VAS) (6 and 12 w) Henry Ford Hospital Headache Disability Inv (4 and 12 w) Secondary: Headache duration (hrs)/day Acute medication Side effects (mild, 21% in each group) | p=0.005<p=0.007 p=0.027 p = 0.06 p = 0.001 NS |
| Harden RN 2009 USA Outpatient Clinic at a Rehabilitation Institute | DB RCT parallel 2 arms Follow up: 12w Diary: 2 w intervals | N: 32 E/C: 12/11 Dropouts: 28% ITT: 23 Age: 45 (9,8) F: 52% | CTHH IHS 2004 Injections: ≤ 4 symptom evaluated Botox® dosage: 100 U, per site: 25 U | Primary: Headache frequency (1-12w) Headache severity (1-12w) Secondary: McGill Pain – SF and Pain Disability Index Trigger point pressure, STAI, HSSES, BDI, ROM Acute medication (Etodolac), Adverse events: Mild, BONTX 8% vs placebo 0 | p=0.013 NS NS NA |

**Trials on CEH**

| First Author Year, Country Setting | Design | Sample/Experimental/Control Dropout rate Age: mean years (SD or range) Female ratio (F %) | Diagnostic criteria Injection technique, Brand BONTX name Total and site dosages | Group comparisons during follow up based on response rates or changes in endpoints from baseline | P values/Statistical significance |
|------------------------------------|--------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------------------------------------------------|----------------------------------|
| Freund BJ 2000 Canada | DB RCT pilot study parallel 2 arms Follow up: 4 w Diary: NA | N: 30 E/C:14/12 Dropout: 13% ITT: NA Age: 46 (29-75) F: 58% | CEH CHISG6.4 (except GON block), WAD II 1 Injections: 5 symptom evaluated Botox® dosage: 100 U Site dose: 20 U | Primary: NA No statistical group comparison, only comparisons to baseline Headache severity (2 w): Headache severity (4 w): AROM (2w) AROM (2w) Adverse events | NS p<0.01 NS |
| Schneider P 2001 Austria | DB RCT parallel 2 arms Follow up: 16 w Diary: 4 w intervals | N: 33 E/C:17/16 Dropout: 3% ITT: NA Age: 51 (26-75) F: 61% | CEH IHS 19986 Injections: 6 symptom evaluated Botox® dose: 90 U Site dose: 15 U | Primary: NA (5-8 w) Headache severity (VAS) Headache frequency (headache-free days/4w), Headache duration (hrs pr day) AROM (sagittal). Local tenderness Acute medication, Adverse events | NS NS NS NS NS |
| Linde M 2011 Norway | DB RCT cross-over 2 arms Follow up: 8 w Diary: 4 w intervals | N: 28 E+C1: 13/15 E2/C2: 14/10 Dropouts: 21% ITT: 28, PP: 26 Age: 46 (26-69) F: 61% | CEH Simpl. CHISG6.5 Injections: 6 fixed sites Botox® dosage: 100U Site dose: 10-20U | Primary: 3 (3-8 w): Headache frequency (moderate to severe) Secondary (3-8 w): Headache intensity (scale 1-3), Headache frequency Headache index (intensity x days/week) Neck pain frequency, Duration of headache/neck pain Proportion ≥30% improved. QoL (at 8w) and AROM, PPT, TTS Acute medication. Adverse events (0-4w) Sick leave (in favour of placebo) | NS NS NS NS NS p<0.001 |
Table 1. (continued)

| First Author Year, Country Setting | Design | Sample/Experimental/Control Dropout rate Age: mean years (SD or range) Female ratio (F %) | Diagnostic criteria Injection technique, Brand BONTX name Total and site dosages | Group comparisons during follow up based on response rates or changes in endpoints from baseline | P values/Statistical significance |
|-------------------------------------|--------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|----------------------------------|
| Karadas Œ 2012 Turkey               | RCT DB: NA parallel 2 arms Follow up: 12 w Diary: NA N: 40 E/C: 20/20 Dropouts: NA ITT: NA Age: 40 (11-23) F: 82% | CEH IHS 2004 Injections: 10 fixed sites Dysport® dosage: 150U Site dose: 10-20U | Primary: NA Pain severity (VAS: 0-100) (6w) Headache frequency 6 w Pain severity (VAS: 0-100) (12 w) Headache frequency (12w) Adverse events | NS p<0.05 p<0.05 p<0.05 NA |                                    |

All trials – a summary

| Countries: Austria: 1 Canada: 1 Egypt: 1 Germany 4 Netherlands: 1 Norway: 1 USA 2 South Africa: 1 Turkey: 1 | DB: 14 trials, SB: 1 trial NA: 1 trial parallel: 14 trials Crossover: 2 trials Follow ups: 4-18 weeks Diary: 2-12 week intervals | Median study sample: N=36.5 (8-300) Median dropout rate (N 11): 6% (0-28%) Median and range of age: 45 (37-54) yrs Median rate of females: 61% (38%-82%) | Diagnostic criteria: For CTTH: IHS 1988, 1997, 2004 and IASP 1994 For CEH: CHISG, HIS. Injection techniques: Fixed sites: 10 trials Symptom evaluated: 5 trials Combination: 1 trial EMG-guided: 1 trial Median no of inj.: 10 (4-22) Botox dosages (13 trials): 20-150 U Dysport dosages (5 trials): 150-500 U | Assessment variables: Diary-based measurements of headache(-free) days per month, duration of headache per day, headache severity/intensity, daily acute medication, or number of days with symptomatic treatment, questionnaire about health status/health related quality of life, psychological distress, functioning, clinical global impression, side effects/ adverse events and sick leave. Examination of AROM, local/pericranial/neck tenderness and pressure pain thresholds, |                                    |

Values presented with numbers, mean and range of means. Abbreviations: IHS: International headache society. CGI: Clinical global impression, NHP: Nottingham Health Profile, ELQ: Everyday-life questionnaire AHPSQ: Analgesics and Headache Pain Specific Questionnaire. STAI= State Trait Anxiety Inventory, HSSES= Headache Specific Self-Efficacy Scale, BDI= Beck Depression Inventory, WHYMPI= West Haven-Yale Multidimensional Pain Inventory, TTHIQ= Tension type Headache Impact Questionnaire. E= Experimental group. C= Control group. U= Unit. Bl= Baseline. FU: Follow up. AE=Adverse event. ROM= Range of movement. CHISG = Headache International Study Group. ¹ [1], ²[2]. IHS= International Headache Society. NA: Not applicable DB= double blinded. SB= single blinded. ³ Some participants had bilateral headache and/or occipital nerve block not performed. ⁴ Median number of injections and age is based on 14 trials. 1. Spitzer WO, Skovron ML, Salmi LR, Cassidy JD, Duranceau J, Suissa S, et al. Scientific monograph of the Quebec Task Force on Whiplash-Associated Disorders: redeﬁning “whiplash” and its management. Spine (Phila Pa 1976). 1995;20(8 Suppl):1s-73s. 2. Sjaastad O, Fredriksen TA, Pfaffenrath V. Cervicogenic headache: diagnostic criteria. The Cervicogenic Headache International Study Group. Headache. 1998;38(6):442-5.
trials [36, 59, 60, 62, 64, 65, 67–69, 71, 72] explicitly reported the numbers who completed, were excluded and/or dropped out, but only eight trials explained why the participants dropped out. Two trials reported no dropouts [64, 65], while five did not comment on this issue [61, 63, 66, 70, 73]. Only four trials presented a flow chart [59, 65, 69, 72], showing the numbers being excluded and participants who dropped out.

Setting

In five of the 16 trials, patients were recruited from a hospital service [60, 64, 69, 72, 73], and in two from a private practice or by advertising [62, 71]. Nine trials did not provide any information of the recruitment process (see Table 1). Eight trials were, and one seemed to be, supported by a pharmaceutical company (see Table 2), and in two trials a pharmaceutical company was or seemed to be involved in the trial report [59, 72].

Patient characteristics

The diagnostic criteria for being included varied across the trials, but included patients equal to or above 18 years of age with the diagnosis CTH or CEH. In most trials this was based on the well-defined criteria from IHS published in either 1988, 1998, 1997 or 2004 (see Table 1 and Supplementary Table 1). Two CEH trials, however, used the criteria from the Headache International Study Group (CHISG) and one [71] included only patients with headache after a cervical whiplash injury. The sample in the latter study may not be representative for CEH patients in general. Two CTH trials aimed to also include patients with episodic tension-type headache [61, 64], and in the first one, 16 of 21 participants had episodic tension-type headache [61]. In the other trial [64] the authors decided not to include a patient with episodic tension-type headache as all the remaining patients had CTH. Six trials [36, 59, 60, 62, 68, 72] accepted ≤1 migraine attack a month or if the patient was able to differentiate from CTH and CEH. In three CTH trials [59, 66, 68], and in three CEH trials [36, 71, 73] inclusion was restricted to patients with a headache history for at least six months. One trial [69] selected only patients where myofascial trigger point palpation reproduced the typical (“concordant”) pain.

Treatment procedure

The injection protocols varied across the trials in terms of strategy, formulation of and dosages of BONTA, number of injection sites (see Table 1), and location (see Supplementary Table 3). Eight CTH trials [59–64, 67, 68] and two CEH trials [72, 73] used a pre-determined approach where BONTA was injected into “fixed sites”, and in five of them with a fixed dose [60–62, 64, 69] (see Table 1). In one trial [60] the “fixed sites” injections were guided by EMG. The symptom-evaluated technique (also termed “follow the pain”) was used in three CTH trials [65, 66, 69] and in two CEH trials [36, 71]. In two of these trials [65, 66] the injections were restricted to sites with increased muscular resistance or local tenderness, while in a third one [69] in specified myofascial trigger points, which triggered the characteristic headache. Finally, one trial [70] combined the two injection strategies. In the trials above, there was no clear description on how trigger points were identified and in one trial [36] the authors did not seem to differentiate between tender or trigger points. The median number of injection sites was eleven (range 4–22) among the CTH trials and six (range 5–10) among the CEH trials.

Most CTH trials applied injections in the neck, shoulder and pericranial musculature, but in three trials [61, 64, 66] to only pericranial musculature, and in one to the frontal muscle [64]. In two of the four CEH trials BONTA was also injected in pericranial muscles [72, 73] (see Supplementary Table 3).

Two different BONTA formulations were applied; 11 trials applied onabotulinumtoxin A (Botox®) manufactured by Allergan Inc (Allergan Inc., Irvine, CA, USA) and five trials abobotulinumtoxin A (Dysport®) manufactured by Ibsen Pharma (Torre Realia, Plaça d’Europa, 41, 08908 L’Hospitalet de Llobregat, Barcelona, Spain) (see Table 1). Straube et al. [59] referred to a publication on equivalency between abobotulinumtoxin A and onabotulinumtoxin A and argue that 2–3 units of abobotulinumtoxin A are equivalent to 1 unit of onabotulinumtoxin A (Allergan Inc., Irvine, CA, USA) [74, 75].

The total dosages of BONTA varied for onabotulinumtoxin A® from 20 to 150 U and for abobotulinumtoxin A from 150 to 500 U. The BONTA dosages varied less across CEH trials, for onabotulinumtoxin A from 90 to 100 U and for abobotulinumtoxin A at 150 U. Among trials, reporting site dosages, they varied from 2 to 40 U for onabotulinumtoxin A and from 12 to 30 U for abobotulinumtoxin A.
Table 2. Quality assessment for 16 randomized placebo-controlled trials on botulinum toxin A treatment for chronic tension type or cervicogenic headache

| Primary author and year of publication | Confirmed support by pharmaceutical industry* | OPVS Sum Score (scale 0-16) | Modified Jadad score (0-8) | Cochrane Risk-of-Bias tool | Consort checklist 25 (confirmed items) | Group comparison of primary end point | Authors' conclusion | Reviewers' conclusion |
|----------------------------------------|-----------------------------------------------|-----------------------------|---------------------------|---------------------------|--------------------------------------|-------------------------------------|---------------------|----------------------|
| Trials on CTTH                          |                                               |                             |                           |                           |                                      |                                     |                     |                      |
| Smuts 1999                              | NA                                            | 9                           | 5                         | HR                        | 9                                    | NA                                  | Positive            | Negative             |
| Rollnik 2000                            | +                                             | 7                           | 4                         | HR                        | 12                                   | NA                                  | Negative            | Negative             |
| Schmidt 2001                            | NA                                            | 16                          | 7                         | SC                        | 18                                   | Negative                           | Negative            | Negative             |
| Rollnik 2001                            | NA                                            | NA                          | 4                         | HR                        | 11                                   | Negative                           | Negative            | Negative             |
| Kokoska 2004                            | +                                             | 16                          | 7                         | SC                        | 26                                   | Positive                           | Positive            | Positive             |
| Padberg 2004                            | +                                             | 16                          | 6                         | SC                        | 21                                   | Negative                           | Negative            | Negative             |
| Relja 2004                              | NA                                            | 5                           | 4                         | HR                        | 7                                    | NA                                  | Positive            | Positive             |
| Schulte-Mattler 2004                    | +                                             | 10                          | 6                         | SC                        | 21                                   | Negative                           | Negative            | Negative             |
| Silberstein 2006                        | +$                                            | 15                          | 7                         | SC                        | 18                                   | Negative                           | Negative            | Negative             |
| Straube 2008                            | +                                             | 12                          | 6                         | SC                        | 23                                   | Negative                           | Negative            | Negative             |
| Hamdy 2009                              | -                                             | 9                           | 5.5                       | HR                        | 13                                   | Positive                           | Positive            | Positive             |
| Harden 2009                             | +                                             | 8                           | 5                         | HR                        | 21                                   | Positive                           | Positive            | Positive             |
| Number/median (range)                   | 6 trials                                       | 10 (5-16)                   | 5.8 (4-7)                 | HR: 6 SC: 6               | 21 (7-26)                            | Negative                           | Positive            | 5                    | Unclear: 1           |
| Trials on CEH                           |                                               |                             |                           |                           |                                      |                                     |                     |                      |
| Freund 2000                             | +                                             | 13                          | 7                         | SC                        | N                                    | NA                                  | Unclear             | Negative             |
| Schnider 2001                           | NA                                            | 7                           | 6                         | HR                        | 11                                   | NA                                  | Negative            | Negative             |
| Linde 2011                              | +                                             | 14                          | 8                         | SC                        | 30                                   | Negative                           | Negative            | Negative             |
| Karadas 2012                            | NA                                            | 8                           | 1                         | HR                        | 12                                   | NA                                  | Positive            | Positive             |
| Number/median (range)                   | 2 trials                                       | 10.5 (7-14)                 | 6.5 (1-8)                 | HR: 2 SC: 2               | 15.5 (11-30)                        | NA: 3                              | Unclear             | 1                    | Unclear: 2           |

OPVS= Oxford Pain Validity Scale, OQS= Oxford Quality Scale, CCL 25= CONSORT Checklist 25, HR= high risk of bias and SC = Some concerns of risk of bias. NA= Not applicable. * Sponsored by pharmaceutical company by grants, support or founding. + Relja et al.: Primary outcome measurement was not defined. $ Harden et al.: Only one of two primary outcome measurements (Headache days/month) favored BONTX treatment (p=0.013). $ The “Botox study group” was involved in the publication.
To define the optimal dosage Silberstein et al. [68] designed a 6-armed trial and injected BONTA dosages of 50 U, 100 U and 150 U or placebo into 10 sites in five muscles, while in two subgroups (BONTA 86Usub and 100Usub) BONTA 86U and 100U, respectively were injected in three and saline in two muscle groups.

Concomitant use of analgesics varied largely across the trials from a strict policy to free allowance for concomitant medication (see Supplementary Table 2). In two trials [59, 72] prophylactic medication were discontinued six and four weeks before randomization, respectively, while a third trial [68] requested the participants to stay on a stable dose of prophylactic headache medication for at least 3 months prior to enrollment, and to use stable doses throughout the trial. For rescue medication one trial [68] accepted only over-the-counter medication, two trials [59, 69] only one single rescue drug, and a fourth trial only if headache severity reached 3 at a 5-point scale [60]. One trial excluded patients using analgesics more than 10 days a month [67]. Although only three trials explicitly reported no limitation for rescue medication [61–63], a total of 11 trials seemed to accept use of analgesics as they registered the consumption of or days with medication [36, 59, 61, 62, 64, 65, 67–70, 72].

Data sampling

All 16 trials used a headache diary to record days with and/or without headache and/or intensity of the headache during a pretreatment interval ranging from 2 to 6 weeks (baseline) and throughout the follow up with intervals ranging from 2 to 8 weeks (Table 1). In four trials the participants were instructed to record one [59, 67], three [69] or four times a day [62].

Primary and secondary outcome measures

Primary outcome measure: Seven of all trials [59, 62, 63, 65, 67, 68, 72] defined one single primary outcome, while three presented two or three primary outcomes, respectively [64, 69, 70]. The only CEH trial [72], defining a primary outcome measure, chose moderate to severe headache frequency. Three CTTH trials [60, 61, 66] and three CEH trials [36, 71, 73] did neither differentiate between primary nor secondary outcomes (see Tables 1 and 2). In Supplementary Tables 4 and 5, primary and secondary variables and variables not specified, are listed for each trial.

Eight trials [36, 61, 62, 65, 69–71, 73] assessed headache intensity by a visual analogue scale: four by a 4 or 5-point verbal scale [59, 66, 67, 72], one [60] by a six-point numeric rating scale (a part of the Chronic Pain Index Score), and one [64] with a combined verbal 4-point and 10-point numeric scale (1–10). In one trial [69] the participants were requested to daily provide a qualitative assessment of the pain (McGill Pain Questionnaire-SF).

Efficacy

Six CTTH trials [59, 62, 63, 65, 67, 68] with predefined primary endpoint and two [60, 61] with no primary endpoint could not find any significant difference between BONTA and placebo treatment (see Table 2). In the multi-armed trial by Silberstein [68], four subgroups (50U, 100U, 100Usub and 86U) a higher number reported ≥50% reduction in headache frequency after 90 days (p: 0.0017–0.024), but after 120 days the difference remained significant for only two of the subgroups (100U and 50U). Notably, placebo treated patients reported a larger increase in headache-free days after 60 days compared with the highest dose of BONTA (150U) (p = 0.007). Correspondingly, Rollnik et al. [61] found higher health status scores (Everyday Life-Questionnaire) among placebo treated patients after both 1 and 3 months.

Four CTTH trials [64, 66, 69, 70] found BONTA treatment statistically superior to placebo (see Table 2), but the second one [66] had no primary endpoint. In two of the trials [64, 69] only one of two primary endpoints was significantly reduced compared with placebo. The trial by Hamdy et al. [70] reported significant group differences for three primary endpoints after 30 and 90 days including headache days per month (p<0.005), headache severity (p<0.007), and headache disability (p<0.027).

In two CEH trials [36, 72], one with predefined primary endpoint, onabotulinumtoxin A was not superior to placebo. A pilot study [71] reported significant improvement from baseline in headache severity and active ROM 4 weeks after BONTA treatment of (onabotulinumtoxin A 100 U), but did not report any statistical comparison to placebo. As this was a pilot study, they did not conclude on effectiveness. Thus, only one CEH trial [73] found BONTA superior to placebo, however, this trial report did neither comment on randomization nor describe the blinding process.

Quantitative synthesis and meta-analysis

Twelve of the trials were included in the quantitative synthesis and meta-analysis (Figure 2A, B), while four were excluded due to insufficient outcome data. In the random-
effects meta-analyses on pain frequency and pain intensity, there was among the CTTH trials a significant difference favoring BONTA on pain intensity (SMD $-0.35$, 95CI $-0.70$ to $-0.002$, p-value 0.049), but not on frequency (SMD $-0.34$, 95CI $-0.71$ to 0.02, p-value 0.066). Among the CEH trials there was a significant effect favoring BONTA on frequency (SMD $-0.74$, 95CI $-1.42$ to $-0.06$, p-value 0.034) and on intensity (SMD $-0.38$, 95CI $-0.74$ to $-0.03$, p-value 0.036).

Side effects

Side effects were recorded in eight out of 12 CTTH trials and in all four CEH trials (see Supplementary Table 9). Among BONTA treated patients, the rates averaged 31% with a range from 0 to 69% and among placebo treated an average of 15% with a range from 0 to 62%. The most common side effects were muscular weakness, headache, and symptoms from the injection site and neck pain, and they were generally mild to moderate and transient in nature.

Low to moderate dosages of onabotulinumtoxin A from 20 U to 150 U [36, 62, 65, 68–73] did not increase the occurrence of side effects. In a trial with high abobotulinumtoxin A dosages (500 units) Schulte-Mattler et al. [67] observed side effects only in the active group. Straube et al. [59] correspondingly found a higher proportion of side effects events after abobotulinumtoxin A 420 units (27%) and 210 units (25%) versus placebo (7%). Dysphagia occurred in 7% after 420 units of abobotulinumtoxin A versus 2% after placebo; and ptosis was only observed in patients receiving 420 units of abobotulinumtoxin A (4%). The proportions, reporting muscle weakness, increased from 6% at 210 units to 18% with 420 units. In the 6-arm trial by Silberstein et al. [68], they, contrastingly, found no consistent dose-response of side effects. In this systematic review there was no significant correlation between BONTA dosages and overall number of side effects.

Validity and quality of the trials and risk of bias

Standardized validity and quality tools provided a detailed assessment of the trials (see Table 2). Among 11 CTTH trials the OPVS scores ranged from 5 to 16 with a median score of 10. Among CEH trials the OPVS scores ranged from 7 to 14 with a median score of 10.5. Five CTTH trials [60, 61, 66, 69, 70] and two CEH trials [73] achieved low OPVS scores <10 due to insufficient information on blinding, small study samples, dropouts, or no correction for multiple testing and in one trial due to a single blinded design (see Table 2). One CTTH trial [63] had a sample size too low to obtain a validity (OPVS) score. The item specific scores of OPVS are presented in Supplementary Table 6.

The Modified Jadad quality score of the CTTH trials ranged from 4 to 7 with a median score of 5.8. For the CEH trials it ranged from 1 to 8 with a median of 6.5 (see Table 2). Separate item scores are presented in Supplementary Table 7. Low Modified Jadad scores reflected inadequate reporting on

---

**Figure 2A:** Standardized mean difference in headache frequency between botulinum toxin A versus placebo in 10 randomized controlled trials. (A) Forest plot where the size of data markers is proportional to study weight.
trial design, lack of information or inappropriate randomization, concealment of allocation or blinding of intervention, withdrawals, how dropouts were handled, or method to assess adverse event described, and for one trial single blinded design. Only five of the trials explicitly described an appropriate blinding process [62, 64, 68, 71, 72] while two trials it was inappropriate [59, 73].

In the supplementary check with the CONSORT Checklist 25 we counted a median of 21 confirmations (range 7–26) among the CTH trials and a median of 15.5 (range 12–30) among the CEH trials (see Table 2).

Six CTH trials [60, 61, 63, 66, 68, 71, 72] were associated with high risk of bias, while six trials [59, 62, 64, 65, 67] with some concerns of risk of bias. Among the four CEH trials, two [36, 73] were associated with high risk and two [71, 72] with some concerns of risk of bias (see Table 2). Separate item scores of the Risk of bias tool (RoB2), describing the reason for risk of bias, are presented in Supplementary Table 8.

The validity (OPVS) and quality scores (Modified Jadad score, Consort Check list 25) were higher in trials with a negative primary endpoint compared with trials with either a positive or not defined primary endpoint, but the statistical comparisons reached statistical significance only for the OPVS (Independent-Samples Kruskal–Wallis Test, N: 15, p=0.01), CCL-25 scores, and CCL-25 (Independent-Samples Kruskal–Wallis Test, N: 16, p=0.034). In pairwise comparisons with Bonferroni corrections significant difference was limited to comparisons to those with no defined primary endpoint (OPVS N:15, p=0.011 and CCL-25 N: 16: p=0.029). The Fisher exact test, correspondingly, revealed higher proportions of trials with a negative primary endpoint when OPVS scores were ≥12 (N: 15, p=0.014), Modified Jadad scores ≥ 6 (N: 16, p=0.031), and numbers of confirmed CCL-25 items were ≥18 (N: 16, p=0.02). The proportion of studies with high risk or bias was also significantly lower among those with a negative primary endpoint (Fisher exact test: N: 16, p=0.014).

Only four trials (25%) used intention-to-treat analysis, seven (44%) described an adequate sequence generation, four (25%) a concealed allocation, and six trials (38%) an adequate blinding (Supplementary Tables 6 and 7). With Fisher exact test we found a positive relationship between the negative primary outcome and blinding (p=0.02), but not to intention-to-treat analysis (p=0.18), concealed allocation (p=0.769), adequacy of sequence generation (p=0.205), or proportion of dropouts (Independent-Samples Kruskal–Wallis Test. N: 16, p=0.200).

Sponsorship has been considered a potential source of bias [76]. We oppositely found a trend towards higher validity (OPVS) and quality in the trials supported by pharmaceutical industry. Only one sponsored trial [59] concluded positively despite negative primary endpoint, and in this case the company had been involved in editing the manuscript.

**Figure 2B:** Standardized mean difference in pain intensity between botulinum toxin A versus placebo in 11 randomized controlled trials. (B) Forest plot based on the endpoint pain intensity (severity). Two trials (Rollnik et al. [61] and Schulte-Mattler et al. [67]) used the product of pain intensity and pain duration (AUC) as endpoint. Size of data markers is proportional to study weight.
Sensitivity analyses

The heterogeneity for the outcomes was high among CTTH and CEH trials (Figure 2), with $I^2$ values of 57.3% (Q=14.05, p=0.029) and 75.3% (Q=8.11, p=0.017), respectively, for the frequency outcomes and $I^2 = 59.9$% (Q=15.0, p=0.021) and 30.5% (Q=4.32, p=0.229), respectively, for the intensity outcomes. One positive CTTH trial [70] and one CEH trial [73], with particular low study quality, had a substantial influence on the pooled standardized effect size. The other trials, however, had no strong influence on the pooled SMD. Assessing the corresponding funnel plots for headache frequency and headache intensity, and the Egger’s regression test for small-study effects, no publication bias was found (p-levels between 0.26 and 0.8). The additional fixed effect and Mandel–Paule empirical Bayes estimator meta-analysis showed comparable results with random-effects meta-analysis (Supplementary Table 10). The meta-regression-based analysis found no significant relationship between the primary outcome and age (p=0.331), sample size (p=0.236), study duration (p=0.484) and dosages (p=0.697), but significant improved BONTA effect with increased proportion of women (p=0.029) when analyzing all trials together (Supplementary Table 11). The Meta-analyses seems robust against biases, but two trials with a strong positive effect influenced the pooled SMD.

Statistical analyses applied in the reviewed trials

In most of the trial reports data was described as means with SD, only one trial used medians [71]. Within- and between-group comparisons were performed with Student’s t-test [60–66, 70] or non-parametric analyses such as Mann–Whitney U test or Wilcoxon tests [59, 65–68, 73]. Some of the trials applied ANOVA [64], GLM ANOVA repeated measure [36, 61, 62, 64, 67, 69–71], non-parametric ANOVA like Kruskal–Wallis Test [68] or Mixed Linear Models [72]. In six trials between-group comparisons of categorical data were carried out with Chi square or Fisher exact test [62–65, 68, 70] and in one trial the McNemar test was used for within-group comparisons [72].

In most trials p-values less than 0.05 indicated statistical significance while one trial [68] defined a statistical p-level of 0.10 for subgroup interaction analyses. One trial performed Tukey’s Studentized range test [64] and three Bonferroni corrections [67, 69, 72] with a stricter significant level for multiple comparisons. Confidence intervals were presented in three trials [59, 65, 72]. Number needed to treat analysis were carried out in only one trial [36].

A large number of the trials demonstrated statistical limitations: Only one trial used ANCOVA to balance for different baseline levels [69], four trials performed intention-to-treat-analysis [59, 68, 69, 72] and only two described how missing values were handled [69, 72]. The computer program for statistical analyses (SPSS or SAS) was described in eight of the 14 trials [36, 64, 65, 67, 69–73].

Discussion

This comprehensive systematic review and meta-analysis cannot confirm a prophylactic effect of botulinum toxin injections or identify any dose-response pattern [59, 68] for CTTH or CEH. Our findings strongly contrast two recent reviews, which included non-randomized, prospective and retrospective cohort studies [33, 34]. BONTA was not superior to placebo treatment in eight of 12 CTTH trials [59, 61–63, 65, 67, 68], and in three of four CEH trials [36, 72]. Trials with negative primary endpoint were associated with higher validity and quality scores compared with trials, favoring BONTA, which “positive” trials were hampered by low quality and high risk of bias. Most trials presented a low standardized mean difference less than 0.5 (see Figure 2), suggesting no clinically meaningful effect of BONTA [77], while three trials had a strong positive effect (two with low quality scores) which explain the slightly positive pooled SMD in the meta-analyses.

Several causes might explain this low ability to demonstrate a BONTA effect [72]. BONTA may be ineffective for CTTH and CEH, but a pain relieving effect of peripheral “needling” and saline/local anesthetic injections or concomitant treatment could also explain the small effect sizes [59]. In one trial [36] the participants additionally received physical therapy (massages and hot mud packs) and in some the trials participants were allowed rescue analgesia. The “negative” trial by Rollnik et al. [61] included patients with episodic tension-type headache and a low headache frequency at baseline (mean 16.2 and SD 10.8) might have reduced the effect size. Due to small effect size the trial by Padberg et al. [65] would need 800 participants to reach a significant group difference.

Standardized validity and quality tools do not evaluate the quality of the intervention/injection procedure itself. It is therefore prudent to question whether the treatment protocols were properly designed in the “negative” trials. None of the studies used an image-guided technique (X-ray with contrast agent or ultrasound), and only one applied EMG guidance to confirm intramuscular needle position [60]. Thus, one could question whether the active component BONTA reached the neuromuscular junctions. Considering
that pericranial muscles are located superficially, we find it more likely that BONTA reached the muscular layer after pericranial injections.

Different injection techniques were applied across the trials, but the “follow the pain” strategy did not demonstrate better results compared with “fixed site” injections. There was a large variation in BONTA dosages across trials and some have argued that BONTA dosages in some trials were too small to obtain a clinical meaningful effect. The phase 3 PREEMPT studies on migraine treatment (PRE-EMPT: Research Evaluating Migraine Prophylaxis Therapy) [26] applied onabotulinumtoxin A dosages of 155 and 195 U, and in the treatment of dystonia 500 units abobotulinumtoxin A have been recommended [78]. The findings by Straube et al. [59] could support this notion: they reported better effect of a high dose (420 units) abobotulinumtoxin A, headache duration, and physician as well as patient’s global assessment were more pronounced compared with low dose (210 units) abobotulinumtoxin A. On the other hand, they reported increased proportion of muscle weakness from 6% at 210 units to 18% at 420 units [59], suggesting that a tolerable limit had been reached. The large dose ranging trial by Silberstein et al. [68] could furthermore not confirm any dose-response of BONTA. After 60 days placebo-treated patients actually reported a larger increase in headache-free days compared to patients who had received 150 units onabotulinumtoxin A.

These higher rates of side effects after BONTA injections might have unblinded participants in some of the trials. In the “positive” trial by Kokoska [64], which included patients with frontal CTTH, three BONTA treated participants reported ptosis vs zero in the placebo group. The three patients (15% of all BONTA treated) were probably unblinded, and this may have interfered with the experienced treatment effect.

The response to saline injections in some of the “negative” trials indicates a placebo effect, although regression towards the mean and the Hawthorne effect cannot be excluded [79]. Placebo responses have been shown in several headache studies [80, 81], and seem to be even higher after invasive procedures [82]. In that case, it suggests adequate blinding of these trials. Supporting this, we found highest validity and quality scores in trials with a negative primary endpoint, in line with a previous systematic review and meta-analysis on acupuncture [42]. This phenomenon clearly illustrates the impact of adequate randomization and blinding in clinical trials [40, 83], and it is notable when two recent systematic reviews [33, 34] on BONTA treatment for CTTH, included low quality, non-randomized and non-controlled cohort studies.

Strength and limitations of the review

This review followed the current PRISMA recommendations for systematic reviews and included a large sample of participants (898 participants) where 535 received BONTA. Eight of the trials chose pain intensity and/or headache frequency as primary endpoint. Both endpoints are clinically relevant and should be sensitive enough to demonstrate a clinically significant difference. The external validity of these findings should therefore be satisfactory.

Other researchers have suggested that repeated injections may increase and prolong the effect of BONTA [32, 65, 66, 84, 85]. This has so far not been tested in randomized, placebo-controlled trials, and we do not have sufficient data to answer this question.

Conclusion

After critically reviewing available data from 16 selected RCTs with a quantitative synthesis and meta-analyses, including 11 of the trials, we cannot conclude that prophylactic BONTA injections are superior to placebo treatment for tension-type headache or cervicogenic headache, irrespective of injection technique and dosage level. Our findings challenge the notion that increased muscular tone or trigger points are responsible for CTTH and support previous studies indicating more complex mechanisms. Also for CEH other mechanisms seem to play a role. To answer the question about efficacy of BONTA injections, future reviews should be based on large, well-designed, randomized, placebo-controlled trials and not non-controlled studies with low validity and quality and a high risk of bias.

Clinical implications

After systematically reviewing 16 selected RCTs on BONTA injection, we cannot recommend prophylactic treatment with BONTA for tension-type headache or cervicogenic headache.

Acknowledgements: The authors would like to thank the librarian at Norwegian University of Science and Technology (NTNU) Ingrid Ingeborg Riphagen, who designed and performed the first database searches in 2014.

Research funding: The authors state no external funding involved.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Competing interests: Authors state no conflict of interest, and they alone are responsible for the content and writing of the paper.

Informed consent: Not necessary for this review of already published trials.

Ethical approval: Not necessary for this review of already published trials.

References

1. IASP. Headache pain; 2020. Available from: https://www.iasp-pain.org/GlobalYear/Headache.

2. Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. J Am Med Assoc 1998;279:381–3.

3. Sjaastad O, Fredriksen TA. Cervicogenic headache: criteria, classification and epidemiology. Clin Exp Rheumatol 2000;18:S3–6.

4. Anthony M. Cervicogenic headache: prevalence and response to local steroid therapy. Clin Exp Rheumatol 2000;18:559–64.

5. Nilsson N. The prevalence of cervicogenic headache in a random population sample of 20-59 year olds. Spine 1995;20:1884–8.

6. Barbanti P, Egeo G, Aurilia C, Foﬁ L. Treatment of tension-type headache: from old myths to modern concepts. Neurol Sci 2014;35;17–21.

7. Chen Y. Advances in the pathophysiology of tension-type headache: from stress to central sensitization. Curr Pain Headache Rep 2009;13:484–94.

8. Martellello P, van Suijlekom H. Cervicogenic headache: practical approaches to therapy. CNS Drugs 2004;18:793–805.

9. Jensen R, Bendtsen L, Olesen J. Muscular factors are of importance in tension-type headache. Headache 1998;38:10–7.

10. Mense S. Muscle pain: mechanisms and clinical signiﬁcance. Dtsch Arztebl Int 2008;105:214–9.

11. Fernandez-de-Las-Penas C. What do we know about chronic tension-type headache? Discov Med 2009;8:232–6.

12. Yu S, Han X. Update of chronic tension-type headache. Curr Pain Headache Rep 2015;19:469.

13. Holroyd KA, Stensland M, Lipchik GL, Hill KR, O’Donnell FS, Cordingley G. Psychosocial correlates and impact of chronic tension-type headache. Headache 2000;40:3–16.

14. Eskim M, Akyol A, Celik EY, Guultekin BK. Social problem-solving, perceived stress, depression and life-satisfaction in patients suffering from tension type and migraine headaches. Scand J Psychol 2013;54:337–43.

15. Leistad RB, Nilsen KB, Stovner LJ, Westgaard RH, Ro M, Sand T. Similarities in stress physiology among patients with chronic pain and headache disorders: evidence for a common pathophysiological mechanism? J Headache Pain 2008;9:165–75.

16. Bendtsen L, Ashina S, Moore A, Steiner TJ. Muscles and their role in episodic tension-type headache: implications for treatment. Eur J Pain 2016;20:166–75.

17. D’Andrea G, D’Amico D, Bussonne G, Bolner A, Aguggia M, Saracco MG, et al. Tryptamine levels are low in plasma of chronic migraine and chronic tension-type headache. Neurol Sci 2014;35:1941–5.

18. Casale R, Tugnoli V. Botulinum toxin for pain. Drugs R 2008;9:11–27.

19. Bezov D, Ashina S, Jensen R, Bendtsen L. Pain perception studies in tension-type headache. Headache 2011;51:262–71.

20. DeLa Vedova C, Cathcart S, Dohmalo A, Lee V, Hutchinson MR, Immink MA, et al. Peripheral interleukin-1ss levels are elevated in chronic tension-type headache patients. Pain Res Manag 2013;18:301–6.

21. Bogduk N, Govind J. Cervicogenic headache: an assessment of the evidence on clinical diagnosis, invasive tests, and treatment. Lancet Neurol 2009;8:959–68.

22. IHS. IHS classiﬁcation ICD-3, secondary headaches. Available from: https://ichd-3.org/introduction-secondary-headaches/.

23. Jaeger B. Are "cervicogenic" headaches due to myofascial pain and cervical spine dysfunction? Cephalalgia 1989;9:157–64.

24. Pfaﬀenrath V, Dandekar R, Pollmann W. Cervicogenic headache— the clinical picture, radiological ﬁndings and hypotheses on its pathophysiology. Headache 1987;27:495–9.

25. Zito G, Jull G, Story C. Clinical tests of musculoskeletal dysfunction in the diagnosis of cervicogenic headache. Man Ther 2006;11:118–29.

26. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. Preempt Chronic Migraine Study Group l. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804–14.

27. Kumar R. Therapeutic use of botulinum toxin in pain treatment. Neuronal Signal 2018;2: NS20180058.

28. Wissel J, Muller J, Dressandt J, Heinen F, Naumann M, Topka H, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manag 2000;20:44–9.

29. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990;28:512–5.

30. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmotic torticolis. Lancet 1986;2:245–7.

31. Mata K, Bolcskei K, Bach-Rojecky L, Helyes Z. Mechanisms of botulinum toxin type A action on pain. Toxins 2019;11. https://doi.org/10.3390/toxins11080459.

32. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. J Am Med Assoc 2012;307:1736–45.

33. Wieckiewicz M, Grychowska N, Zietek M, Wieckiewicz G, Smardz J. Evidence to use botulinum toxin injections in tension-type headache management: a systematic review. Toxins 2017;9:370.

34. Freund B, Rao A. Efficacy of botulinum toxin in tension-type headaches: a systematic review of the literature. Pain Pract 2019;19:541–51.

35. Evers S, Rahmann A, Vollmer-Haase J, Husstedt IW. Treatment of headache with botulinum toxin A—a review according to evidence-based medicine criteria. Cephalalgia 2002;22:699–710.

36. Schneider P, Moraru E, Vigi M, Wöber C, Földy D, Maly J, et al. Physical therapy and adjunctive botulinum toxin type A in the treatment of cervical headache: a double-blind, randomised, placebo-controlled study. J Headache Pain 2002;3:93–9.

37. Hobson DE, Gladish DF. Botulinum toxin injection for cervicogenic headache. Headache 1997;37:253–5.

38. Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inf Decis Making 2007;7:16.
74. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004;19: S129–36.
75. Guttman C. Equipotent doses of botulinum toxin type A products share same radius of action. Dermatol Times 2005;66.
76. Zhuang L, He J, Zhuang X, Lu L. Quality of reporting on randomized controlled trials of acupuncture for stroke rehabilitation. BMC Compl Alternative Med 2014;14:151.
77. Carson C. The effective use of effect size indices in institutional research: Google Scholar; 2012. Available from: http://www.keene.edu/ir/effect_size.pdf.
78. Wissel J, Kanovsky P, Ruzicka E, Bares M, Hortova H, Streitova H, et al. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol 2001;248: 1073–8.
79. Leonard KL. Is patient satisfaction sensitive to changes in the quality of care? An exploitation of the Hawthorne effect. J Health Econ 2008;27:444–59.
80. Harden RN, Gracely RH, Carter T, Warner G. The placebo effect in acute headache management: ketorolac, meperidine, and saline in the emergency department. Headache 1996;36:352–6.
81. Pfaffenrath V, Diener HC, Isler H, Meyer C, Scholz E, Tanner Z, et al. Effectiveness and tolerance of amitriptyline oxide in chronic tension headache - a multicenter double-blind study versus amitriptyline versus placebo. Nervenarzt 1993;64:114–20.
82. Diener HC, Schorn CF, Bingel U, Dodick DW. The importance of placebo in headache research. Cephalalgia 2008;28:1003–11.
83. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I: Medical. Stat Med 1989; 8:441–54.
84. Dodick DW. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside. Headache 2003;43:525–33.
85. Evans RW, Blumenfeld A. Botulinum toxin injections for headache. Headache 2003;43:682–5.

Supplementary Material: The online version of this article offers supplementary material (https://doi.org/10.1515/sjpain-2021-0038).